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Implications for Rehabilitation 
Dysfunctional breathing (DB) is associated with significant patient morbidity but often 
goes unrecognised, leading to prolonged investigation and significant use of health 
care resources. There is mounting, but not conclusive evidence supporting the use of 
breathing retraining for the management of this condition. However, increased 
knowledge is required about the epidemiology, aetiology, pathophysiology and 
natural history of this disorder. A large scale RCT evaluating the efficacy of breathing 
retraining in primary DB is warranted. 
 
Physiotherapists are using manual therapy (MT) as an adjunctive treatment for 
patients with DB. However, there is little consensus regarding the nature of the 
proposed connective and muscular tissue lesions that these techniques purport to 
address. In addition, there is no validated tool to identify and quantify these 
abnormalities and their potential response to therapy. Therefore, the additional use of 
MT provides no further benefit and cannot be recommended in the clinical 
management of this condition 
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Does Manual Therapy Provide Additional Benefit To Breathing Retraining In The 
Management Of Dysfunctional Breathing? A Randomised Controlled Trial 
M Jonesa, F Troupb, J Nugusc, M Roughtond, ME Hodsonc,e, C Raynerf, F Boweng, JA Pryorc 
 
INTRODUCTION 
Dysfunctional breathing (DB) is a psychologically (primary) or physiologically (secondary) based 
respiratory disorder associated with significant patient morbidity [1]. It is characterised by an 
abnormal breathing pattern [2-5], presented by combinations of erratic breathing [2, 6, 7], 
episodic breath holding and sighing [2, 8] or hyperventilation [2, 8]. In DB, thoracic excursion 
predominantly occurs from the upper rather than lower chest and diaphragm [8]. DB occurs in 
approximately 6-11% of the general patient population and accounts for symptoms in up to 40% 
of patients’ in general medical outpatient clinics [2]. Rapid recognition of DB is essential to 
increase the chance of appropriate management [6].  
 
Although the precise mechanisms underlying DB are poorly understood, the focus of treatment 
is reversal of over-breathing through respiratory physiotherapy [1]. Current physiotherapy 
management consists of breathing retraining, with the patient being taught diaphragmatic 
breathing control, relaxation techniques and DB education [1, 9, 10]. Treatment aims to restore 
and maintain a normal diaphragmatic breathing pattern and in some cases, re-programme the 
respiratory center to trigger inspiration at a higher level of carbon dioxide [1, 10]. Evidence 
exists to support this approach in both primary DB [11-14] and DB occurring secondary to 
chronic cardiorespiratory disease, such as asthma [6, 15] and cardiac failure [16,17].  
 
Increasingly, physiotherapists in the UK [10] and internationally [18] are using manual therapy 
(MT) as a treatment component in the management of primary and secondary DB [19]. 
Proponents of these techniques suggest that DB produces structural and functional changes to 
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the musculoskeletal system [20]. In particular, dominance of the accessory muscles of 
respiration, thoracic spine hypo-mobility, increased tonicity of the abdominal muscles restricting 
diaphragmatic movement, costovertebral dysfunction or increased myofascial tone are seen in 
these patients.  Additionally, due to the Bohr effect [21], the lowered levels of carbon dioxide 
inhibit the transfer of oxygen from haemoglobin to the tissue cells, which may lead to ischemia, 
fatigue and pain [10] and the evolution of myofascial trigger points [20]. Such trigger points 
purportedly change the activation of the entire kinetic chain [22], altering both movement and 
breathing patterns, impeding normal respiratory function secondary to poor posture. These 
musculoskeletal adaptations are believed to influence respiratory function, perpetuating the 
abnormal respiratory pattern [10]. As such, proponents argue that patients with DB may find 
normalisation of their breathing pattern difficult with breathing retraining alone, and advocate MT 
(‘muscle energy techniques’ ‘diaphragm doming’ and ‘rib raising’) to reverse the musculoskeletal 
abnormalities [10].  
 
Although benefits of MT in DB are reported anecdotally, no robust evidence exists to validate 
these claims. This study sought to investigate the hypothesis that MT produces additional 
benefit when compared with breathing retraining alone in a group of patients with primary DB. 
 
METHODS 
Subjects 
Between July 2007 and January 2009, 60 subjects aged 18-88 years were recruited to this 
parallel study from the respiratory outpatient clinic at a London postgraduate teaching hospital 
and three private physiotherapy practices. Each patient had a clinical diagnosis of DB following 
a positive Nijmegen score [4, 23] (score >23). Patients with metastatic disease, osteoporotic 
disease, respiratory infection or DB as a consequence of asthma or cardiac disease were 
excluded from the study.  
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Following written consent, computerised randomisation was undertaken by an independent 
researcher, with subjects assigned to either respiratory management (standard treatment group; 
n=30) or respiratory management plus MT (intervention group; n=30). The study protocol was 
approved by Brompton, Harefield & NHLI Ethics Committee. 
 
Interventions  
Following randomisation, throughout the study, subjects were individually assessed and treated 
at each session, according to the study protocol, by one of two experienced physiotherapists. 
Data collection took place at Royal Brompton & Harefield NHS Foundation Trust.  Both groups 
received standardised respiratory physiotherapy management:  1) an explanation and education 
of the mechanisms and symptoms associated with DB, including developing self-awareness of 
breathing pattern; 2) identification of “trigger factors” to DB response, plus management / 
minimisation strategies 3) breathing retraining involving diaphragmatic breathing control at rest 
in sitting, lying or standing [1, 10] with gradual normalisation of respiratory frequency; 4) 
diaphragmatic breathing during and following exertion; 5) a diaphragmatic breathing regimen to 
practice at home for 4 x 10 minutes daily at an agreed respiratory frequency; 6) a breathing 
retraining programme compact disc [24] with pre-recorded tracks providing auditory cues for 
accurate practice of breathing control techniques. This programme was reaffirmed at each visit, 
and progression made based on individual subject response. In addition, subjects randomised 
to the intervention group received an individualised selection of MT techniques (based on the 
limited existing literature in this area), in response to musculoskeletal abnormalities identified 
following a standardised assessment. This involved observation of dynamic and static posture, 
assessment of active and passive ranges of movement (neck, thoracic, shoulder joints), muscle 
length tests (cervico-scapulo-thoracic musculature), joint accessory glides (costovertebral, 
cervical, thoracic, glenohumeral, acromioclavicular joints), myofascial palpation and rib 
expansion measurement. Techniques employed included 1) muscle and joint mobilisation 
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techniques, for example Maitland mobilisations [25], muscle energy techniques, trigger point 
therapy, myofascial and positional release techniques [26]; 2) diaphragm doming [27]; 3) rib 
raising [28].  
 
Outcome measures 
The primary outcome measure was change from baseline in the Nijmegen score. The Nijmegen 
Questionnaire has been validated as a tool for the diagnosis of DB [4].  A score of >23 has been 
shown to correlate positively with DB [23]. Secondary outcome measures were change from 
baseline in 1) spirometry measured by forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC); 2) breath hold time [3] (a short breath hold time is usually associated with a 
low or unstable resting PaCO2; 3) exercise capacity (6-minute walk test [29] with oximetry, 
undertaken in accordance with American Thoracic Society Statement Guidelines [30]; 4) 
Hospital Anxiety and Depression Scale (HADS) [31]; 5) musculoskeletal measurements: 
cervical lateral flexion (a gross measure of tightness in neck muscles), bilateral shoulder flexion 
with spine in neutral (a measure of restriction in upper back) and chest expansion, through 
circumferential measurement of rib expansion at the level of the 7th thoracic vertebra.  
 
Subjects were assessed on entering the study, with outcome measures undertaken at baseline, 
then repeated at 2, 4, 8, 12 and 26 weeks, before a treatment session based on their allocated 
group. The outcome measures were undertaken by an independent observer blinded to the 
subject’s treatment allocation. In addition to planned outcome measurement sessions, subjects 
in both groups received further physiotherapy treatment dependent on individual clinical 
assessment findings, as reflective of contemporary clinical practice.  
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Sample size calculation 
Using existing data from the Lung Function Laboratory, at Royal Brompton & Harefield NHS 
Foundation Trust, the predicted mean baseline Nijmegen score was 27 (SD 10). It was 
calculated that 25 subjects were required in each group to provide a study with 80% power to 
show an absolute reduction in Nijmegen score of 9 and 17 in the standard and intervention 
group respectively at a significance level of 0.05. To allow for a 20% dropout during the course 
of the study 60 subjects were recruited (30 in each arm).  
 
Statistical analysis 
Continuous data are summarised as mean (SD) and categorical data as N (%). The effect of MT 
on all outcome measures was assessed using a mixed-effects linear regression model. The 
data from each subject visit were entered into the model, with subjects declared as a random 
effect due to the repeated nature of the data. The estimate of the treatment effects were 
adjusted for time and baseline values, and presented as mean difference between the groups 
along with 95% confidence intervals. Paired t-tests were used to assess the within group 
changes from baseline to the final visit for each subject. A secondary analysis comparing the 
change in each group from baseline to final visit was carried out using un-paired t-tests. Missing 
data from subjects who withdrew from the study was not imputed. All analyses were performed 
using Stata 10 (StataCorp, Texas) and a p value of less than 0.05 was used to determine 
statistical significance. All other p values are presented for completeness only. 
 
RESULTS 
60 subjects (30 per group) were recruited into the trial. The analysis comprised all 57 subjects 
who achieved at least 1 follow up visit, (3 subjects; 1 respiratory group, 2 MT group, failed to 
attend any further sessions following baseline assessment). Twenty-seven and 28 subjects in 
the respiratory and MT arm respectively, completed baseline and a minimum of 3 follow-up 
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sessions. In addition, to the 5 pre-determined outcome measurement sessions, some subjects 
from both study groups received additional interim treatment sessions as reflective of clinical 
practice. Subjects in the MT group received more treatment sessions than those in the standard 
therapy group (Respiratory Group 6.3 (SD 2.2) sessions vs. MT Group 9.1 (SD 3.4) sessions; 
p<0.001).  Data were analysed on an intention to treat basis, with no cross-over between study 
groups. All treatments were delivered in full without any documented adverse events. The 
respiratory group had higher Nijmegen scores at baseline, and was younger (Table 1). At 
baseline, demonstrable musculoskeletal (MSK) problems, consistent with those described in the 
literature, were identified in all subjects in both groups.  Subjects had one or more of the 
following MSK problems, presented in different combinations and to differing degrees in 
individual subjects: over active accessory muscles, postural abnormalities, reduced range of 
movement affecting cervical and thoracic spine, glenohumeral joint with poor scapulohumeral 
rhythm, myofascial trigger points and tight paracervical and thoracic musculature. The 
identification of techniques for each individual subject was based on assessment findings 
undertaken before each treatment session. Most commonly used techniques included: mobility 
exercises, postural education, muscle and joint mobilisation techniques (Maitland mobilisations 
and rib rising), trigger point therapy / myofascial and positional release techniques, muscle 
energy techniques and diaphragm doming.  
 
Insert table 1 here 
 
There was no significant difference between the intervention and standard treatment groups for 
the primary outcome (Nijmegen score), or any secondary outcomes (Table 2). After adjusting for 
baseline values, the Nijmegen score of the MT group fell by an average of 2.8 points less than 
the respiratory group (95% CI (-1.1, 6.6) p=0.162) (Table 2); For Nijmegen score, lower values 
are associated with less severe symptoms. Additionally, there was no difference in the rate of 
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change for Nijmegen score between the two groups (Figure 1). There was no treatment effect 
on lung function, with both FEV1 (p=0.453) and FVC (p=0.914) showing little evidence of effect. 
 
Inset table 2 here 
 
Insert figure 1 here  
 
Within group comparisons showed significant improvements in the primary and several 
secondary outcomes for both study groups (Table 3). In the MT group the Nijmegen score fell 
by 12.6 (9.0) points and by 17.6 (13.6) points in the respiratory group (p<0.001 for both), with 
normalisation of Nijmegen seen in over 65% of subjects (21/28, MT group and 19/29, 
respiratory group; p=0.56). Statistically significant improvements were also seen in both groups 
for HADs, breath hold length, bilateral shoulder flexion and cervical flexion.  
 
Insert table 3 here  
 
DISCUSSION 
In this study, statistically significant improvements in DB, as documented by decreased 
Nijmegen score and normalisation of the Nijmegen score in over 65% of subjects in both study 
groups. In addition, within group improvements were also found in several secondary outcomes 
including HADS, 6-minute walk, breath hold test and some musculoskeletal measurements. 
However, contrary to our hypothesis, the application of MT techniques demonstrated no 
additional benefit to breathing retraining.  
 
Although this study was not specifically designed to investigate the efficacy of breathing 
retraining per se, the improvement in Nijmegen score and the number of subjects with a 
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normalised Nijmegen score seen in both groups is consistent with the existing, but limited 
literature in this area. A pilot study [12] evaluating four different approaches to the management 
of primary DB reported significant improvements in symptoms following a 12-week course of 
breathing retraining and relaxation. This finding was supported by a controlled study [13], which 
established a 10-week programme of breathing exercises using an incrementally adjusted 
ventilatory retraining device, was successful in the management of primary DB. Significant 
improvements in psychological factors, symptom complaints and respiratory dimensions were 
also noted. In an uncontrolled interventional trial [14], Han et al concluded that breathing 
retraining with a physiotherapist over 2-3 months, resulted in significantly reduced Nijmegen 
score and anxiety levels in 92 subjects with primary DB; positive results were attributed to 
reduced respiratory frequency observed following treatment. DeGuire et al reported breathing 
retraining through paced diaphragmatic breathing had both short term [16] and lasting effects 
[17] on respiratory physiology and highly correlated with a reduction in reported functional 
cardiac symptoms in 41 patients with cardiac disease and associated DB. The results of our 
study concur with an earlier RCT [6]; evaluating physiotherapy based breathing retraining 
versus nurse-led asthma education for asthmatic patients with DB. This group reported half their 
subjects showed a fall in Nijmegen score, which correlated with a clinically relevant 
improvement in quality of life following physiotherapy; this improvement was maintained in a 
quarter of subjects’ 6-months later. These findings were supported by a 2007 RCT [15], which 
concluded that breathing retraining and relaxation (The Papworth Method) significantly reduced 
respiratory symptoms and DB, while improving health related quality of life and adverse mood, 
compared with usual care in a group of 36 patients with asthma. In this study, based on 
literature of other chronic respiratory disease, a clinically significant improvement in HADS [32] 
was found in both study groups, and the 6-minute walk test [33] in the respiratory management 
group. Furthermore, statistically significant improvements were observed in secondary 
musculoskeletal indices in both study groups; this suggests that these changes may have 
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occurred secondary to reversal of DB and normalisation of Nijmegen through breathing 
retraining.  
 
We believe this is the first RCT to evaluate the use of MT in the management of primary DB. 
Osteopathic and chiropractic MT dates back to the beginning of the 20th century and focuses on 
mobilising the ribs and thoracic spine to increase thoracic expansion, with claims of improved 
lung function, quality of life, arterial oxygen content and lymphatic return [20, 21]. The use of 
such techniques for non-spinal or extremity pain has caused controversy and debate in the 
literature [19]. Although the proposed physiological mechanisms underpinning these techniques 
remain poorly understood, reports of improved outcomes following their application exist for 
asthma [34, 35], pneumonia [36] and paediatric respiratory infections [37]. Bronfort et al (2001) 
[34] undertook a prospective clinical case series combined with an observer-blinded, pilot 
randomised clinical trial investigating the effect of chiropractic spinal manipulative therapy 
(SMT) in addition to optimal medical management in 36 paediatric subjects with mild and 
moderate asthma. They concluded that after 3 months of combining chiropractic SMT with 
optimal medical management, subjects rated their quality of life substantially higher and their 
asthma severity substantially lower, with improvements maintained at 1-year follow up. 
However, the authors stated that the results could not be attributed to the specific effects of 
chiropractic SMT alone. Furthermore, no control group data were published for comparison.  
 
A recent RCT [35] investigating the effects of osteopathic manipulative treatment (OMT) on 
paediatric patients with asthma reports a statistical but clinically insignificant improvement in 
peak expiratory flow rate (PEFR) following intervention. However, they report within group not 
between group comparative data. In addition, there was no evidence of statistical adjustment for 
baseline inequalities, with the control group demonstrating more severe airflow obstruction. In a 
well-designed RCT, Balon et al (1998) [38] investigated the effects of chiropractic SMT versus 
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simulated chiropractic SMT over 4-months in paediatric subjects with asthma. They reported no 
significant difference in outcome for PEFR at 2 or 4-months, symptoms of asthma, use of ß-
agonists, quality of life, spirometric measurements or airway responsiveness. They concluded 
that chiropractic SMT provided no additional benefit to usual medical care in children with mild 
or moderate asthma. Indeed, this paper accounts for more than 50% of the subjects (1 of 3 
papers) considered in a recent Cochrane systematic review [19], which concluded “there is 
insufficient evidence to support the use of manual therapies for patients with asthma”. This 
finding was confirmed by a recent UK evidence report which reviewed chiropractic and 
osteopathic MT [39].  
 
Limitations of the study 
This study was conducted in a single center; however subjects with DB were recruited from both 
primary and secondary care. The recruited subjects were predominantly female (43:17), but this 
is consistent with the existing literature.  
 
In this study sham MT was not employed and all clinical interventions were undertaken by two 
experienced, but un-blinded physiotherapists. However, computer aided randomisation occurred 
centrally and all baseline and subsequent assessments were undertaken by an independent 
single physiotherapist who had no knowledge of subjects study arm allocation.  
 
Although data collection was incomplete for some subjects (3 subjects lost to follow-up), 27 and 
28 subjects in the respiratory and MT arm respectively, completed baseline and a minimum of 3 
follow-up sessions, within the range of our original power calculation (minimal n=25 in each 
study arm). Indeed, although not statistically significant, the improvements in Nijmegen score, 
our primary outcome, were greatest in the control (respiratory) group – making it unlikely that a 
true benefit for MT was missed. 
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We recognise that our decision to apply multiple and individualised MT may make it difficult to 
tease out the therapeutic benefit of different individual and / or combinations of techniques.  
However, a pragmatic choice was made to use a relevant but restricted number of MT, which 
mirrors contemporary clinical practice, where a range of MT is often applied together. Therefore, 
this study cannot advise regarding additional techniques not employed, nor can possible 
interactions between the techniques be excluded.  
 
Implications 
DB is associated with significant patient morbidity but often goes unrecognised, leading to 
prolonged investigation and significant use of health care resources. There is mounting, but not 
conclusive evidence supporting the use of breathing retraining for the management of this 
condition. However, increased knowledge is required about the epidemiology, aetiology, 
pathophysiology and natural history of this disorder. A large scale RCT evaluating the efficacy of 
breathing retraining in primary DB is warranted. 
With reference to MT, there is little consensus regarding the nature of the proposed connective 
and muscular tissue lesions, that these techniques purport to address. In addition, there is no 
validated tool to identify and quantify these abnormalities and their potential response to 
therapy. Therefore, before any further application of such techniques in patients with DB is 
justifiable, further research centered on these issues is required. 
 
Conclusion 
Breathing retraining is currently the mainstay of treatment for patients with DB. Based on the 
results of this study, the additional use of MT provides no further benefit and cannot be 
recommended in the clinical management of this condition. 
(Words 3012) 
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Trial Registration  
Full protocol available at http://clinicaltrials.gov/ct2/show/NCT00895219 
Registration number NCT 00895219 
Ethical Approval: The study protocol was approved by Brompton, Harefield & NHLI Ethics 
Committee. 
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Respiratory 
group 
Manual Therapy 
group p value 
Measurement N=30 N=30   
Age (years) 41.7 (13.5) 50.8 (13.0) 0.001* 
Male 10 (33.3) 7 (23.3) 0.390 
Weight (kg) 78.1 (24.4) 70.8 (16.0) 0.183 
Height (m) 170.6 (10.5) 166.5 (8.2) 0.096 
BMI 26.7 (7.5) 25.4 (6.0) 0.476 
Nijmegen score 38.6 (9.5) 31.5 (6.9) 0.001* 
HAD Anxiety 11.6 (4.2) 10.0 (4.5) 0.174 
HAD Depression 6.5 (3.0) 5.9 (3.9) 0.534 
Breath hold (seconds) 25.5 (13.7) 22.8 (9.1) 0.367 
Cervical flexion right (cm) 36.8 (9.3) 35.4 (7.9) 0.542 
Cervical flexion left (cm) 33.5 (8.1) 33.3 (7.3) 0.953 
Bilateral shoulder flexion 
(degrees) 152.1 (29.3) 145.6 (31.6) 0.411 
Chest expansion (cm) 3.57 (1.76) 3.98 (1.44) 0.329 
FEV1 2.97 (0.69) 2.66 (0.81) 0.207 
FVC 3.65 (1.27) 3.42 (0.99) 0.437 
SPO2 pre walk test (%) 96.7 (1.31) 97.0 (1.1) 0.423 
HR pre walk test (bpm) 76.5 (15.7) 73.4 (9.2) 0.423 
Borg Dyspnoea pre walk test 1.86 (1.25) 2.09 (1.36) 0.509 
Borg Fatigue pre walk test 2.11 (2.14) 1.91 (2.03) 0.726 
6MWT distance (m) 523.3 (139.5) 465.3 (144.6) 0.123 
Borg Dyspnoea post walk test 3.91 (1.75) 3.89 (1.86) 0.966 
Borg Fatigue post walk test 3.46 (2.28) 3.27 (2.81) 0.775 
Table 1: Characteristics and baseline values of study subjects All values mean 
(SD) except male, which is N (%). * Indicates statically significant difference 
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Measurement 
Treatment 
effect 95% CI 
p 
value 
Nijmegen score 2.8 -1.1 6.6 0.162 
HAD Anxiety 0.6 -0.8 2.0 0.394 
HAD Depression 0.3 -0.6 1.2 0.505 
Breath hold (seconds) 1.4 -2.0 4.8 0.412 
Cervical flexion right (cm) -1.8 -4.4 0.9 0.190 
Cervical flexion left (cm) -0.7 -2.8 1.4 0.518 
Bilateral shoulder flexion 
(degrees) 4.1 -2.3 10.5 0.213 
Chest expansion (cm) -0.1 -0.4 0.2 0.632 
FEV1 0.02 -0.04 0.09 0.453 
FVC 0.01 -0.09 0.10 0.914 
SPO2 pre walk test (%) 0.0 -0.3 0.3 0.824 
HR pre walk test (bpm) 1.2 -1.2 3.6 0.326 
Borg Dyspnoea pre walk test 0.0 -0.5 0.4 0.960 
Borg Fatigue pre walk test 0.1 -0.4 0.7 0.651 
6MWT distance (m) -10.5 -32.9 11.8 0.356 
Borg Dyspnoea post walk test -0.1 -0.5 0.4 0.789 
Borg Fatigue post walk test -0.1 -0.6 0.5 0.733 
 
Table 2: Analysis of primary and secondary outcomes All results adjusted for 
baseline and visit number. The treatment effect represents the difference between 
the changes in the manual therapy (MT) relative to the respiratory arm for each 
variable. A positive treatment effect indicates that the final value for that parameter 
was greater in the MT arm relative to that in the respiratory arm. For Nijmegen score 
it should be noted that a lower score is desirable, therefore, a positive treatment 
effect for this variable means patients in the MT group decreased by less than those 
in the respiratory group.  
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  Change from baseline to last visit 
Measurement MT group p value Resp group p value 
Nijmegen score -12.6 (9.0) <0.001* -17.6 (13.6) <0.001* 
HAD Anxiety -2.5 (3.8) 0.002* -4.1 (5.4) 0.001* 
HAD Depression -2.3 (2.6) <0.001* -2.4 (3.8) 0.002* 
Breath hold (seconds) 8.5 (8.4) <0.001* 6.6 (12.6) 0.012* 
Cervical flexion right (cm) 6.2 (9.0) 0.001* 7.0 (9.2) <0.001* 
Cervical flexion left (cm) 4.9 (8.3) 0.005* 5.1 (8.3) 0.003* 
Bilateral flexion (degrees) 14.9 (21.5) 0.001* 6.9 (20.1) 0.081 
Chest expansion (cm) 0.6 (1.3) 0.031* 0.7 (1.0) 0.001* 
FEV1 0.01 (0.31) 0.891 -0.08 (0.14) 0.008* 
FVC 0.07 (0.39) 0.334 -0.04 (0.22) 0.339 
SPO2 pre walk test (%) 0 (1.0) 1.000 0.2 (1.0) 0.383 
HR pre walk test (bpm) -2.9 (8.5) 0.149 -3.9 (8.5) 0.054 
Borg Dyspnoea pre walk 
test -0.9 (1.6) 0.011* -0.7 (1.8) 0.059 
Borg Fatigue pre walk test -0.6 (1.2) 0.031* -0.6 (3.1) 0.336 
6MWT distance (m) 31.9 (137.0) 0.256 65.9 (56.7) <0.001* 
Borg Dyspnoea post walk 
test -1.4 (1.7) 0.001* -1.2 (2.1) 0.012* 
Borg Fatigue post walk test -0.9 (2.2) 0.066 -0.9 (2.4) 0.069 
 
 
Table 3: Within group changes from baseline to final follow up visit  
All values mean (SD). * Indicates statically significant difference.   
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3, 4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 4 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants 4 
4b Settings and locations where the data were collected 5 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
5 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
5,6 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 6 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 4 
8b Type of randomisation; details of any restriction (such as blocking and block size) N/A 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
4 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
4 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 5 
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CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 6 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses N/A 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
4, 6, 7 
13b For each group, losses and exclusions after randomisation, together with reasons 6,7 
Recruitment 14a Dates defining the periods of recruitment and follow-up 6 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 8 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
6 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
9,10,10,11, 
12 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
N/A 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 7 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 15 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 16 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 16 
Other information  
Registration 23 Registration number and name of trial registry 16 
Protocol 24 Where the full trial protocol can be accessed, if available 16 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 16 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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CONSORT Flow Diagram 
 
Analysed (n=29) 
♦ Excluded from analysis (only underwent 
baseline assessment and 1 treatment session) 
(n=1) 
Lost to follow-up (give reasons) (n=1) 
Discontinued intervention (n= 0) 
Allocated to standard treatment (n=30) 
♦ Received allocated intervention (n= 30) 
♦ Did not receive allocated intervention (give 
reasons) (n= 0 ) 
Lost to follow-up (give reasons) (n=2) 
Discontinued intervention (n=0) 
Allocated to intervention (n=30) 
♦ Received allocated intervention (n= 30) 
♦ Did not receive allocated intervention (give 
reasons) (n=0 ) 
Analysed (n=28)  
♦ Excluded from analysis (only underwent 
baseline assessment and 1 treatment session) 
(n= 2) 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 60) 
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